MY182680A - Antibody formulation and therapeutic regimens - Google Patents

Antibody formulation and therapeutic regimens

Info

Publication number
MY182680A
MY182680A MYPI2016001562A MYPI2016001562A MY182680A MY 182680 A MY182680 A MY 182680A MY PI2016001562 A MYPI2016001562 A MY PI2016001562A MY PI2016001562 A MYPI2016001562 A MY PI2016001562A MY 182680 A MY182680 A MY 182680A
Authority
MY
Malaysia
Prior art keywords
seq
glutamic acid
antibody
heavy chain
light chain
Prior art date
Application number
MYPI2016001562A
Other languages
English (en)
Inventor
Holly Zhuohong Huang
David Andrew Martin
David H Salinger
Christopher Boyd Russell
Christopher J Endres
Scott Walter Baumgartner
Dingjiang Liu
Original Assignee
Amgen K A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY182680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen K A Inc filed Critical Amgen K A Inc
Publication of MY182680A publication Critical patent/MY182680A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
MYPI2016001562A 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens MY182680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10

Publications (1)

Publication Number Publication Date
MY182680A true MY182680A (en) 2021-01-29

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016001562A MY182680A (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Country Status (38)

Country Link
US (5) US8883151B2 (index.php)
EP (3) EP3632466A1 (index.php)
JP (2) JP5743234B2 (index.php)
KR (1) KR101766936B1 (index.php)
CN (1) CN102821787B (index.php)
AR (1) AR079903A1 (index.php)
AU (3) AU2011205402B2 (index.php)
BR (1) BR112012017150B1 (index.php)
CA (1) CA2787128C (index.php)
CL (1) CL2012001966A1 (index.php)
CO (1) CO6640206A2 (index.php)
CR (1) CR20120419A (index.php)
CY (2) CY1119852T1 (index.php)
DK (2) DK2523688T3 (index.php)
EA (2) EA201891433A3 (index.php)
ES (2) ES2753216T3 (index.php)
HR (1) HRP20171939T1 (index.php)
HU (2) HUE046670T2 (index.php)
IL (1) IL220602B (index.php)
IN (1) IN2012DN06720A (index.php)
LT (2) LT3295957T (index.php)
MA (1) MA33989B1 (index.php)
MX (1) MX349856B (index.php)
MY (1) MY182680A (index.php)
NO (1) NO2523688T3 (index.php)
NZ (1) NZ601125A (index.php)
PE (1) PE20121691A1 (index.php)
PH (1) PH12012501364A1 (index.php)
PL (2) PL3295957T3 (index.php)
PT (2) PT3295957T (index.php)
RS (2) RS59743B1 (index.php)
SG (2) SG182468A1 (index.php)
SI (2) SI3295957T1 (index.php)
TN (1) TN2012000335A1 (index.php)
TW (1) TWI554282B (index.php)
UA (1) UA112288C2 (index.php)
WO (1) WO2011088120A1 (index.php)
ZA (1) ZA201205167B (index.php)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PL3295957T3 (pl) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Formulacja przeciwciała przeciwko IL-17RA i reżimy terapeutyczne do leczenia łuszczycy
DK2531218T3 (en) * 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
EP2619226B1 (en) * 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2012240050B2 (en) * 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP6203740B2 (ja) 2011-11-23 2017-09-27 アムジェン インコーポレイテッド アルファ４ベータ７ヘテロ二量体特異抗体の投与
MX362191B (es) * 2012-03-07 2019-01-08 Lilly Co Eli Formulacion de anticuerpo il-17.
ES2622558T3 (es) 2012-05-14 2017-07-06 Novo Nordisk A/S Soluciones proteínicas estabilizadas
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
AP2015008801A0 (en) 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
AU2015241373B2 (en) * 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR102427097B1 (ko) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
WO2016039319A1 (ja) * 2014-09-10 2016-03-17 日油株式会社 蛋白質吸着抑制剤及び蛋白質吸着抑制方法
EP3763384B1 (en) 2014-12-03 2024-08-28 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
WO2017112536A1 (en) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 as a predictor of clinical response to il23-antagonists
US10222674B2 (en) 2016-04-19 2019-03-05 Sage Electrochromics, Inc. Electrochromic device including a transparent conductive oxide layer and a bus bar and a process of forming the same
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
SG11202100185VA (en) 2018-07-13 2021-02-25 Astrazeneca Collaboration Ventures Llc Treating ulcerative colitis with brazikumab
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
JP2022547678A (ja) * 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
CA3167975A1 (en) * 2020-02-18 2021-08-26 Amgen, Inc. Formulations of human anti-tslp antibodies and methods of using the same
CN112891531B (zh) * 2020-06-19 2021-10-08 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
EP4537345A1 (en) * 2022-06-06 2025-04-16 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ATE119942T1 (de) 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
CA2032191C (en) 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU674292B2 (en) 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
CA2133326C (en) 1992-03-30 2005-03-01 Craig A. Smith Fusion proteins comprising tumor necrosis factor receptor
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
AU696775B2 (en) 1995-03-23 1998-09-17 Kirin-Amgen, Inc. IL-17 receptor
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
ES2242966T3 (es) 1995-07-19 2005-11-16 Genetics Institute, Llc Ctla-8humana y usos de proteinas relacionadas con ctla-8.
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN100389821C (zh) 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
JP2003526370A (ja) 2000-03-16 2003-09-09 アムジェン インコーポレーテッド Ｉｌ−１７レセプター様分子およびその使用
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CA2425506A1 (en) 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
US20050153880A1 (en) 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP2007501251A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物を使用する感染予防
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
EP1751234A4 (en) 2004-06-04 2009-04-15 Designer Molecules Inc RADICALLY HARDENABLE POLYESTERS AND METHOD OF USE THEREOF
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
PL1933869T3 (pl) 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
US20070129302A1 (en) 2005-10-18 2007-06-07 Zeren Gao Il-17c antagonists and methods of using the same
EP3593790A1 (en) 2005-11-01 2020-01-15 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
WO2008049070A2 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EA200901154A1 (ru) 2007-03-26 2010-04-30 Займодженетикс, Инк. Растворимые слитые белки il17ra/rc и родственные способы
US20110008356A1 (en) 2007-06-13 2011-01-13 Amgen, Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
AU2008289225A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
MX2010009100A (es) 2008-02-21 2010-12-06 Amgen Inc Antagonistas de il-17ra-il-17rb y uso de los mismos.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PL3295957T3 (pl) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Formulacja przeciwciała przeciwko IL-17RA i reżimy terapeutyczne do leczenia łuszczycy
RU2591083C2 (ru) 2010-10-08 2016-07-10 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
EP3214442A1 (en) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
EP2694708A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY
AU2012240050B2 (en) * 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
KR102427097B1 (ko) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법

Also Published As

Publication number Publication date
ZA201205167B (en) 2013-03-27
BR112012017150A2 (pt) 2017-10-10
SG182468A1 (en) 2012-08-30
CY1122466T1 (el) 2020-10-14
EA031209B1 (ru) 2018-12-28
DK3295957T3 (da) 2019-10-14
AU2011205402A1 (en) 2012-07-12
SI3295957T1 (sl) 2020-02-28
PH12012501364A1 (en) 2012-10-22
JP5743234B2 (ja) 2015-07-01
AR079903A1 (es) 2012-02-29
ES2753216T3 (es) 2020-04-07
KR20120118036A (ko) 2012-10-25
MX2012008213A (es) 2012-11-06
MX349856B (es) 2017-08-16
US20180346583A1 (en) 2018-12-06
TW201129382A (en) 2011-09-01
LT3295957T (lt) 2020-01-27
EA031209B9 (ru) 2021-11-19
US10808033B2 (en) 2020-10-20
CY1119852T1 (el) 2018-06-27
US20230192873A1 (en) 2023-06-22
PL3295957T3 (pl) 2020-03-31
RS56781B1 (sr) 2018-04-30
PL2523688T3 (pl) 2018-04-30
CA2787128A1 (en) 2011-07-21
NO2523688T3 (index.php) 2018-03-10
US20150017184A1 (en) 2015-01-15
PT2523688T (pt) 2018-01-05
EP2523688B1 (en) 2017-10-11
PT3295957T (pt) 2019-11-12
AU2015202023B2 (en) 2017-05-18
ES2652637T3 (es) 2018-02-05
EA201891433A3 (ru) 2019-02-28
IN2012DN06720A (index.php) 2015-10-23
EP3632466A1 (en) 2020-04-08
EA201290653A1 (ru) 2013-02-28
HUE035618T2 (en) 2018-05-28
AU2015202023A1 (en) 2015-05-14
US20200399384A1 (en) 2020-12-24
RS59743B1 (sr) 2020-02-28
EP2523688A1 (en) 2012-11-21
SG10201604093XA (en) 2016-07-28
IL220602B (en) 2019-03-31
CL2012001966A1 (es) 2013-01-18
AU2017216579A1 (en) 2017-09-07
WO2011088120A8 (en) 2012-09-13
UA112288C2 (uk) 2016-08-25
JP2013517277A (ja) 2013-05-16
CR20120419A (es) 2012-11-29
CA2787128C (en) 2019-06-11
TN2012000335A1 (en) 2013-12-12
CN102821787B (zh) 2015-07-29
BR112012017150B1 (pt) 2022-03-03
EA201891433A2 (ru) 2018-11-30
US10072085B2 (en) 2018-09-11
EP3295957A1 (en) 2018-03-21
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
JP2015052017A (ja) 2015-03-19
TWI554282B (zh) 2016-10-21
WO2011088120A1 (en) 2011-07-21
WO2011088120A9 (en) 2012-08-09
LT2523688T (lt) 2018-03-12
DK2523688T3 (en) 2017-12-04
EP3295957B1 (en) 2019-08-07
CO6640206A2 (es) 2013-03-22
US8883151B2 (en) 2014-11-11
HUE046670T2 (hu) 2020-03-30
KR101766936B1 (ko) 2017-08-09
AU2011205402B2 (en) 2015-02-05
NZ601125A (en) 2014-08-29
PE20121691A1 (es) 2012-12-14
HRP20171939T1 (hr) 2018-03-23
MA33989B1 (fr) 2013-02-01
US11505612B2 (en) 2022-11-22
CN102821787A (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
MY182680A (en) Antibody formulation and therapeutic regimens
JP2013517277A5 (index.php)
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
ES2757675T3 (es) Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile
CN102164613B (zh) 中和抗甲型流感病毒抗体及其用途
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ719036A (en) Anti-pdl1 antibody formulations
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
TWI377212B (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
ES2729278T3 (es) Anticuerpos neutralizantes de las exotoxinas principales tcda y tcdb de Clostridium difficile
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
PE20050586A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr
PE20170687A1 (es) Proteinas de enlace a cd127
ES2564281T3 (es) Formulación de anticuerpos Abeta
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
PE20191242A1 (es) Formulaciones de anticuerpo y metodos
NZ622583A (en) Protein formulations and methods of making same
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
RU2013142004A (ru) Конъюгаты "антитело-лекарственное средство"
RU2010121874A (ru) Антиген, ассоциированный с ревматоидным артритом